What is Elara Pharmaceuticals's latest funding round?
Elara Pharmaceuticals's latest funding round is Grant.
How much did Elara Pharmaceuticals raise?
Elara Pharmaceuticals raised a total of $6.4M.
Who are the investors of Elara Pharmaceuticals?
Investors of Elara Pharmaceuticals include BMBF GOBio, BioRN - Biotechnologie Rhein-Neckar, EMBL Ventures, Wagnisfinanzierungsgesellschaft fuer Technologiefoerderung in Rheinland-Pfalz and KfW.
Who are Elara Pharmaceuticals's competitors?
Competitors of Elara Pharmaceuticals include Kythera Biopharmaceuticals, Idenix Pharmaceuticals, ugichem, Callisto Pharmaceuticals, Excaliard Pharmaceuticals and 13 more.
You May Also Like
BioMarck Pharmaceuticals is a biopharmaceutical company dedicated to the discovery and development of drugs for the treatment of pulmonary diseases and disorders associated with the over-secretion of mucus and pulmonary inflammation. In developing its lead compound, BIO-11006 Inhalation Solution, BioMarck has chosen chronic obstructive pulmonary disease (specifically chronic bronchitis) as its first target, but other diseases including asthma, and cystic fibrosis are later disease targets. BIO-11006 Inhalation Solution works by a novel dual mechanism; it inhibits both the secretion of mucus in the lungs and pulmonary inflammation. These aspects of BIO-11006 Inhalation Solution have been demonstrated in several different animal models. In addition, BioMarck has completed a full panel of preclinical safety studies, has an active IND with the FDA, has completed two BIO-11006 in Phase 1 clinical studies, and is currently conducting a Phase 2 study of the efficacy of BIO-11006 in COPD patients.
ugichem is developing antisense drugs based on its proprietary Ugimer platform for unmet medical needs in immune-mediated inflammatory diseases (IMID). Ugimers overcome the shortcomings of standard antisense technologies or RNAi. In contrast, Ugimers are not derived from natural nucleic acids but are based on the peptide nucleic acid (PNA) backbone and carry specific side chains for improved delivery, efficacy and specificity. This innovative design provides Ugimers with unique biopharmaceutical properties allowing them access to previously inaccessible organs, cells and cellular compartments, including the immune system. Moreover, Ugimers are the first and only antisense drugs that have efficacy in mitochondria.
Affectis Pharmaceuticals, fka neuronova, is a biopharmaceutical company developing drugs for the treatment of psychiatric and inflammatory disorders.
NeED Pharmaceuticals is a biopharmaceutical company focused on the discovery and development of anti-infective drugs for the treatment of serious and neglected infectious diseases, where a large unmet medical need and market opportunity are clearly present.
Inflazyme Pharmaceuticals is a biopharmaceutical company engaged in the discovery, development and commercialization of therapies for the treatment of respiratory and inflammatory diseases. The company's core focus is medicinal chemistry based, orally active, small molecules aimed at treating unmet medical needs.
Longevica is a biotechnology that is researching mechanisms of healthy aging and life extension. The company is also developing an open research tool for scientists and research institutions to access a data set that tracks the effects of pharmacological compounds for testing drugs.
Discover the right solution for your team
The CB Insights tech market intelligence platform analyzes millions of data points on vendors, products, partnerships, and patents to help your team find their next technology solution.